GenMark Expects to File Respiratory Virus, CYP2C19 Tests with FDA in 2012 | GenomeWeb

By Justin Petrone

Two additional GenMark Diagnostics test panels may be available for clinical use in the US next year, CEO Hany Massarany said last week.

Massarany said that the Carlsbad, Calif.-based molecular-diagnostics firm is on track to submit its respiratory virus panel to the US Food and Drug Administration for 510(k) clearance before the end of the year. The panel allows users to test samples for the presence of 21 upper respiratory viruses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.